Windtree Therapeutics (NASDAQ: WINT) is up 142% at our pixel time on the back of news about the grant of a European patent. Which is nice, obviously. That's down some 40% or so from the peaks reached when the news came though - not so good for some. What interests us - because we're cynics - is that this patent news also came through as WINT was pricing a stock offer. Which is that terribly convenient thing, isn't it?
Windtree is a fairly standard pharma development company in its economic structure. Debt finance really isn't available until there's some asset that debt can be secured against. Such an asset, in pharma, is an FDA or similar approval to sell a drug or treatment. By definition, if you're developing such a thing then there is no such asset as yet - that's exactly the thing which is being developed. So, like all development stage pharma companies WINT lives off regular injections of shareholder capital. This is fine, this is just the way the sector works. The usual idea is that there is continued dilution from periodic stock issues. No one funds the whole process at the start because we want to see the milestones - patent, Phase I, Phase II and so on - being passed before we out here fund the next stage.

Windtree Therapeutics share price from NASDAQ
So, stock issue is announced, dilution coming up, the stock price falls. This is all entirely normal.
Then we get the interesting bit:

WINT stock price from NASDAQ
There's the announcement that a European patent has been granted. The stock price doubles and triples on this news.
Yet in the drug development game a patent is the first stage. Getting one of those is really pretty easy. It's getting the drug that is patented through the trials to FDA or equivalent approval that is difficult and expensive. But, you know, announcement, the stock price doubles and or triples.
Which is interesting. Because Windtree has not as yet priced that new stock offer. The details for WINT are here. The price is going to be at prevailing market price. Or some discount to. But what will be the market price they're using as the prevailing one? A nice bounce in that stock price - say, a doubling or tripling - reduces the dilution cost of the new equity raise.
In the SEC document there they do point out that they're not wholly sure that the issue at then market prices would leave them as a going concern for 12 months. But if the price were a bit higher they could raise more and they would be.
No, no, no. No! We agree entirely that coincidences do happen. We have indeed met some random old lady at the train station and helped her up the stairs with her suitcase only to find out later that she's Granny's best friend. Coincidences do happen.
But, you know. We're not wholly and fully convinced about the current higher value of WINT stock. Can't quite pin down why not but we're not.